Age: 14.0
Sex: F
Vaccine: COVID19
Symptoms: Condition aggravated, Dyspnoea, Pulmonary function test, Pulmonary function test decreased, Wheezing
Clinical narrative: Pulmonary function test revealed significant decrease in pulmonary function as compared to six months ago.; difficulty breathing at rest and particularly with activity.; increased wheezing; Symptoms improved however worsened after the second vaccine and have continued to be worse than prior to first vaccination.; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 14 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 24Oct2021 17:00 (Lot number: FF2593) at the age of 14 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "Asthma" (unspecified if ongoing); "Known allergy: Penicillin" (unspecified if ongoing). Concomitant medication(s) included: ALBUTEROL SULFATE. Vaccination history included: Bnt162b2 (Dose number: 1, Lot number: FF8839, Dose administration time : 04:00 PM, Vaccine location: Left arm), administration date: 30Sep2021, when the patient was 14 years old, for Covid-19 immunization, reaction(s): "increased wheezing", "difficulty breathing at rest and particularly with activity". The following information was reported: DYSPNOEA (non-serious) with onset Oct2021, outcome "not recovered", described as "difficulty breathing at rest and particularly with activity."; WHEEZING (non-serious) with onset Oct2021, outcome "not recovered", described as "increased wheezing"; CONDITION AGGRAVATED (non-serious) with onset Oct2021, outcome "not recovered", described as "Symptoms improved however worsened after the second vaccine and have continued to be worse than prior to first vaccination."; PULMONARY FUNCTION TEST DECREASED (non-serious), outcome "not recovered", described as "Pulmonary function test revealed significant decrease in pulmonary function as compared to six months ago.". The events "difficulty breathing at rest and particularly with activity.", "increased wheezing", "symptoms improved however worsened after the second vaccine and have continued to be worse than prior to first vaccination." and "pulmonary function test revealed significant decrease in pulmonary function as compared to six months ago." were evaluated at the physician office visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of dyspnoea, wheezing, condition aggravated, pulmonary function test decreased.  Additional information: No other vaccine received in four weeks. Facility type vaccine was pharmacy or drug Store. No Covid prior vaccination. No Covid tested post vaccination. Clinical course: Medications received in two weeks was albuterol inhaler. patient was asthmatic and well controlled with medications. Due to worsening symptoms, she went on prednisone and was taking increased medication. AE treatment was oral prednisone and symbicort. Albuterol. AE resulted in doctor or other healthcare professional office/clinic visit.  Follow-up attempts are completed. No further information is expected.